Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners

REHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI Drug Discovery Roadshow, taking place November 2-5, 2026, across the U.S. East Coast.

Organized by the Israel Export Institute and TradeIL, the roadshow aims to strengthen connections between Israel's leading AI-driven drug discovery and biotechnology companies and the U.S. life sciences ecosystem, creating opportunities to engage with investors, pharmaceutical companies, and potential strategic partners.

Evogene will be represented by Mr. Ofer Haviv, President and Chief Executive Officer, who will present the company's unique computational chemistry platform, ChemPass AI™, a proprietary generative AI platform for discovering and optimizing novel small molecules. The platform can explore vast chemical spaces and identify promising candidates designed to meet multiple critical parameters simultaneously, supporting the discovery of novel molecules with optimized profiles for drug development.

Through its participation, Evogene aims to expand its presence in the U.S. pharmaceutical and biotechnology markets, establish new strategic relationships, and advance collaboration opportunities in AI-driven drug discovery. Mr. Haviv will be available for meetings with interested investors, pharmaceutical companies, and potential partners throughout the roadshow. Interested parties are invited to contact Evogene to arrange a meeting.

Roadshow Details:

• Date: November 2-5, 2026
• Location: New York, New Jersey, Philadelphia, Washington, D.C., and Maryland
• Organizer: Israel Export Institute and TradeIL

About Evogene Ltd.: 

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.

At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com.

Forward-Looking Statements:  

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses ChemPass AI™ as an enabler of new opportunities for collaborative drug discovery with pharmaceutical and biotech partners and as an accelerator for the discovery and optimization of novel small molecules for drug development. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact

[email protected]
Tel: +972-8-9311901

SOURCE Evogene